EGFR and glioblastoma: In early 2024, Choi et al. reported results from three patients with recurrent GBM treated with CARv3-TEAM-E T-cells targeting epidermal growth factor receptor (EGFR) wild-type and epidermal growth factor receptor variant III (EGFRvIII) [86].